AnaptysBio Files for IPO

September 11, 2015

Share:

AnaptysBio, a biotech developing antibody products focused on inflammation and immuno-oncology, has filed for an IPO and plans to list shares on the NASDAQ under the symbol ANAB. A portion of the estimated $86 million in proceeds will go to fund the development of two of AnaptysBio's main drug candidates and their initial clinical trials. The company has raised roughly $89 million in equity financing from investors including Frazier Healthcare (23.2% pre-IPO stake), Novo (21.3%) and Avalon Ventures (15.2%).